The high-profile trial of former Theranos CEO Elizabeth Holmes boils down to a single question: Did she cover up defects in her startup’s blood-testing technology to rip off investors while potentially endangering the lives of unwitting patients
Related posts
-
Developer pulls plug on Arlington 425 project plagued by delays and financing woes
The ambitious Arlington 425 development that would have transformed the face of downtown Arlington Heights and... -
Chicago’s O’Hare is second busiest in the world for flights, No. 8 in passengers
Chicago is still a bridesmaid to Atlanta in the busy airport stakes, but O’Hare officials expect... -
Growing the game: DuPage golf preserve revenues top $8 million
Revenue generated by all three golf courses run by the Forest Preserve District of DuPage County...